Versant enters obesity with new startup

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hullo! Today, some squiddy drug delivery, a leukemia deal between Kura Oncology and Kyowa Kiri, and a new GLP-1 startup from Versant Ventures.

Kura Oncology inks leukemia drug deal with Kyowa Kiri

Kura Oncology just partnered with Japan’s Kyowa Kiri in a $330 million licensing deal to develop and sell its experimental drug for acute leukemia. Kura developed ziftomenib, which belongs to a class of blood cancer drugs called menin inhibitor by targeting certain mutations and “rearrangements” of genes, STAT’s Adam Feuerstein writes.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In